Doctor of Osteopathy Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Jennifer Avena

Adult Medicine Las Vegas, NV Doctor of Osteopathy

NPI 1578528998 CMS profile 252448

5701 W Charleston Blvd Ste 210, Las Vegas, NV 89146

Open in the dashboard

General payments

$350

19 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Jennifer Avena of Las Vegas, NV is reported in the CMS Open Payments database as having received $350 across 19 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 54th percentile of Adult Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $176 9
2022 General $39 2
2021 General $44 2
2020 General $34 2
2019 General $57 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jennifer Avena
  • Adult Medicine median
  • Middle half of Adult Medicine
  • National median

In program year 2025, general payments to Jennifer Avena were reported at $0. Among 691 Adult Medicine profiles paid that year, the median was $151 and the middle half received between $51 and $528.

Show as a table
Year Jennifer Avena Adult Medicine median Middle half National median
2019 $57 $140 $41–$517 $163
2020 $34 $107 $25–$378 $114
2021 $44 $136 $32–$529 $132
2022 $39 $138 $39–$492 $149
2023 $176 $155 $46–$483 $160
2024 $0 $153 $46–$554 $164
2025 $0 $151 $51–$528 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Pfizer Inc. $118 5 payments
  2. ANI Pharmaceuticals, Inc. $65 3 payments
  3. Grifols USA, LLC $30 2 payments
  4. Baxter Healthcare $17 1 payment
  5. OPKO Pharmaceuticals, LLC $17 1 payment
  6. Abbott Laboratories $17 1 payment
  7. Electromed, Inc. $16 1 payment
  8. Amgen Inc. $16 1 payment
  9. Amarin Pharma Inc. $15 1 payment
  10. AstraZeneca Pharmaceuticals LP $14 1 payment
  11. Other $25 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $350 19 payments
Products named General payments · program years 2019–2023
  1. PAXLOVID $69 3 payments
  2. ELIQUIS $65 3 payments
  3. PURIFIED CORTROPHIN GEL $65 3 payments
  4. NURTEC ODT $43 2 payments
  5. Prolastin-C Liquid $30 2 payments
  6. PREVNAR 13 $28 1 payment
  7. PREVNAR 20 Vaccines $28 1 payment
  8. PREVNAR 20 Vaccines $26 1 payment
  9. COMIRNATY $26 1 payment
  10. Hillrom - Life 2000 Ventilation System $17 1 payment
  11. Other $120 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 55 drugs

Part D claims

1,829

Median for Family Practice: 1,826

Drug cost

$156,227

Median for Family Practice: $120,094

Branded share of claims

14.1%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rybelsus Semaglutide Brand 15 $32,495
Ozempic Semaglutide Brand 13 $26,061
Xarelto Rivaroxaban Brand 13 $17,203
Jardiance Empagliflozin Brand 11 $15,574
Januvia Sitagliptin Phosphate Brand 11 $14,201
Farxiga Dapagliflozin Propanediol Brand 18 $13,913
Nurtec Odt Rimegepant Sulfate Brand 12 $11,515
Breo Ellipta Fluticasone/Vilanterol Brand 16 $6,108
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 22 $2,193
Albuterol Sulfate Hfa Albuterol Sulfate Brand 50 $2,117

The 10 drugs with the highest cost, of 55 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$16,882

Medicare's payments for the services billed

Medicare patients

51

Average age 72

Services billed

254

40 women, 11 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 39%
Diabetes 33%
Heart failure 27%
Ischemic heart disease 27%
Chronic kidney disease 27%
COPD 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

19 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Adult Medicine in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record